Navigation Links
Chimerix to Present at Infocast's 9th Annual Biodefense Vaccines & Therapeutics Conference
Date:7/20/2011

ses. 250 patients have received CMX001 under Emergency Investigational New Drug Applications (EINDs), including for treatment of orthopox viruses. A significant number of the individuals receiving CMX001 in human testing have been immunocompromised as a result of disease or immunosuppressing therapies associated with stem cell or solid organ transplantation.

Clinical studies of CMX001 include an ongoing Phase 2 study for the prevention/control of cytomegalovirus (a herpes virus) in adult hematopoietic stem cell transplant patients (CMX001-201); a Phase 2 study for the treatment of adenovirus infection in pediatric and adult hematopoietic stem cell transplant patients (AdV HALT Trial/CMX001-202); and an Open-Label Study (CMX001-350) for the treatment of dsDNA viral infections. The open-label study builds on Chimerix's extensive experience working with over 150 clinicians at over 80 leading institutions in the United States, Canada, Europe, and Israel who have sought CMX001 under EINDs for the treatment of immunocompromised patients.

CMX001 and Smallpox Antiviral Development

CMX001 is a leading antiviral candidate as a medical countermeasure against a smallpox release, including the potential to provide an important therapeutic option for the 80 million people in the U.S. currently estimated to be immunocompromised and thus not candidates to receive a smallpox vaccine. Chimerix has received federal funding for the development of CMX001 as a medical countermeasure against smallpox from the National Institute of Allergy and Infectious Diseases under Grant No. UO1-AI057233 and from the Biomedical Advanced Research and Development Authority (BARDA), Office of the Assistant Secretary for Preparedness and Response, Office of the Secretary, Department of Health and Human Services, under Contract No. HHSO100201100013C.

About Chimerix

Chimerix is developing novel antiviral therapeutics with the potential to transform patient car
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Chimerix Appoints Timothy W. Trost Senior Vice President, Chief Financial Officer
2. Chimerix to Present at Cowen and Company 31st Annual Health Care Conference
3. Disseminated Adenovirus Infection Eradicated in a Pediatric Hematopoietic Stem Cell Transplantation Recipient Who Received Chimerixs Lead Antiviral CMX001
4. Chimerix to Present at the Citi 2011 Global Health Care Conference
5. Chimerix Commences CMX001 Open-Label Clinical Study for the Treatment of Patients With Life-Threatening or Serious dsDNA Viral Infections
6. Chimerixs Antiviral CMX157 Demonstrates Positive Phase 1 Clinical Results With Favorable Pharmacokinetics, Safety and Tolerability
7. Chimerix to Present at the Lazard Capital Markets 7th Annual Healthcare Conference
8. Chimerix Reaffirms Its Commitment to CMX001 as a Medical Countermeasure for Smallpox and Broad-Spectrum Antiviral Agent
9. Chimerix to Present at 9th Annual BIO Investor Forum
10. Chimerix Appoints Thomas Pitler, Ph.D., Vice President, Business Development
11. Chimerix Initiates Phase 2 Study of CMX001 in Stem Cell Transplant Recipients Seropositive for Cytomegalovirus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... 27, 2015 Levi & Korsinsky announces it ... OHRP ) concerning possible violations of federal securities ... Company in connection with its study of the drug ... or contact Joseph E. Levi, Esq. ... telephone at (212) 363-7500, toll-free: (877) 363-5972. ...
(Date:3/27/2015)... MONTREAL , March 27, 2015 /CNW Telbec/ - ... Research-Based Pharmaceutical Companies (Rx&D), welcomes the 2015-2016 ... of a working group on the biopharmaceutical industry. However, ... medicines budget. "We commend the government,s intent ... the announcement of measures to promote Quebec,s ...
(Date:3/27/2015)... The Temple Health & Bioscience District (THBD) today announced it ... South First St. in the Temple Medical and Education District ... of Temple to receive funding for redevelopment. Located ... Health Care System, the new facility will enable THBD to ... life science companies. Temple ...
Breaking Medicine Technology:Quebec 2015-2016 Budget: Rx&D welcomes fiscal discipline and biopharma working group, but the decrease in government spending on medicines is questioned 2Quebec 2015-2016 Budget: Rx&D welcomes fiscal discipline and biopharma working group, but the decrease in government spending on medicines is questioned 3Temple Health & Bioscience District Relocates, Offers Office And Lab Space To Biotech Companies 2
... 2011 Samplify Systems, Inc., a leading provider of ... scientific markets, has completed its Series B round of ... fund its rapid growth in its existing markets, and ... the round are Integrated Device Technology, Inc. (Nasdaq: ...
... THOUSAND OAKS, Calif., March 4, 2011 Amgen (Nasdaq: ... the acquisition of BioVex Group, Inc., a privately held ... in Abingdon, UK. The acquisition includes OncoVEX(GM-CSF), a novel ... may represent a new approach to treating melanoma and ...
Cached Medicine Technology:Samplify Systems Completes Series B Funding 2Samplify Systems Completes Series B Funding 3Amgen Completes Acquisition of BioVex 2Amgen Completes Acquisition of BioVex 3Amgen Completes Acquisition of BioVex 4
(Date:3/28/2015)... 28, 2015 Andrew Hawley of Vintage Rock ... psychedelic concert posters. The Who and the Doors played together ... 2, 1968. According to Hawley, “The Who toured the United ... and college campuses. Perhaps the most famous Who poster was ... and the Doors on August 2, 1968 at the Singer ...
(Date:3/28/2015)... Aureus Medical Group (web: aureusmedical.com), ... therapy jobs, has announced that it will participate ... Association Annual Conference to be held April 10-11, ... Columbus, OH. , The OPTA Annual Conference ... products and services. , Representatives from Aureus ...
(Date:3/28/2015)... 2015 The "Petrick Sustainable Health ... health. After 18 years of research and experience with ... contenders, Dr. Jon Petrick is excited to be launching ... of the immediate benefits of this radical new system ... of strength of the immune system, faster healing of ...
(Date:3/28/2015)... March 28, 2015 ARDX will sponsor the ... 12pm -3pm at the Chesapeake Conference Center in Chesapeake, Virginia. ... an empowering event for women in the Hampton Roads region. ... Stories of Women’s Lives. Women grow stronger through sharing ... other. This year the WWC™ theme is T-talk where ...
(Date:3/28/2015)... 28, 2015 Servpro of Paso ... week released a report about the link between mold ... sufferers, and according to recent medical research, may even ... to the Environmental Protection Agency, people with sensitivity to ... in mold may trigger asthma attacks for asthma sufferers. ...
Breaking Medicine News(10 mins):Health News:Avid Collector from Vintage Rock Posters, Inc. Announces His Search For Original 1960's Who Psychedelic Concert Posters. 2Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the Ohio Physical Therapy Association Annual Conference 2Health News:Celebrity Chiropractor Jon Petrick to Release Sustainable Health System this Summer 2Health News:Water Damage Restoration Specialists Servpro of Paso Robles Release Report on Mold and Asthma 2Health News:Water Damage Restoration Specialists Servpro of Paso Robles Release Report on Mold and Asthma 3
... peers are doing seems to matter, expert surmise, , MONDAY, ... friends really weren,t drinking as much as it might seem, ... , Researchers from Oxford Brookes University in England reviewed 22 ... States. The researchers divided the students into two groups: those ...
... NASHVILLE, Tenn., July 20 HealthLeaders-InterStudy, a leading ... the Los Angeles market are struggling to recruit physicians, particularly ... the recent Los Angeles Market Overview , ... to physicians, ranging from $250 to $4,000 a day, to ...
... , PITTSBURGH, July 20 Mylan Inc. (Nasdaq: ... million preferred stock issuance, the company has declared its quarterly dividend of ... a liquidation preference of $1,000.00 per share) payable on August 17, 2009, ... , , Mylan Inc., which provides products ...
... , SEATTLE, July 20 Group Health ... 15 quality measures in the Puget Sound Health Alliance Community ... any of the other nine medical groups in the Puget Sound region ... Health received no "below regional average" scores. , , ...
... , , CLEVELAND, July 20 ... global eClinical solutions for the clinical trials industry, announced today that ... DATATRAK CRO Connect Program(TM). ARA will utilize DATATRAK eClinical(TM) to ... paper and EDC clients. , , ...
... , , ... 20 Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX ) today announced that ... drug for the treatment of obesity, met their co-primary endpoints. The results ... besity R esearch, or COR, program of more than 4,500 ...
Cached Medicine News:Health News:Perception May Affect Drinking by College Students 2Health News:l.a. Hospitals Struggle for Emergency Room Care, Pay Physicians High Fees for On-Call Coverage 2Health News:Group Health Cooperative Scored Above Regional Average in 11 of 15 Quality Measures 2Health News:Advance Research Associates Joins DATATRAK's CRO Connect Program(TM) 2Health News:Advance Research Associates Joins DATATRAK's CRO Connect Program(TM) 3Health News:Advance Research Associates Joins DATATRAK's CRO Connect Program(TM) 4Health News:-Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments- 2Health News:-Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments- 3Health News:-Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments- 4Health News:-Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments- 5Health News:-Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments- 6Health News:-Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments- 7Health News:-Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments- 8Health News:-Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments- 9
... ,The S/5 Critical Care Monitor is a multiparameter ... varying needs of critical care. The S/5 Critical ... options, display and mounting options, remote control and ... set-up to help meet your needs. The new ...
... for size., ,The Datex-Ohmeda S/5 Light Monitor ... in anesthesia and critical care areas, in emergency ... transport. As part of the Datex-Ohmeda S/5 family, ... user interface and design shared by all S/5 ...
... to use., ,The S/5 Compact Critical ... ideally suited for medium care monitoring. The ... Datex-Ohmeda supplies and accessories., ,The S/5 ... user interface and features as the S/5 ...
... need in day surgery and post anesthesia care ... Anesthesia Monitor is a high performance monitor designed ... anesthesia care and induction rooms. It offers the ... parameters and advanced airway gas monitoring. When paired ...
Medicine Products: